PCM
AGIO icon

Price Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Price Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-11,475
Closed -$1.29M – 305
2014
Q4 		$1.29M Buy
+11,475
New +$1.02M 1.13% 43

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Price Capital Management's AGIO Position: Q1 2015 in Review

Price Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2015, closing a stake of 11,475 shares — an estimated $1.29M sold.

Price Capital Management first reported a position in AGIO in Q4 2014 and held it in 1 quarter. The position peaked at $1.29M in Q4 2014. 152 funds tracked by Wall St. Rank hold AGIO as of Q1 2015.

  • Price Capital Management reported no remaining Agios Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Price Capital Management sold 11,475 Agios Pharmaceuticals shares in Q1 2015, an estimated $1.29M.
  • Price Capital Management first reported a position in Agios Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Price Capital Management's Agios Pharmaceuticals position peaked at $1.29M in Q4 2014.
  • 152 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2015.

Based on Price Capital Management's 13F filing for Q1 2015, filed 13 May 2015.